

DAFTAR PUSTAKA

1. Barbieri RL. Breast. Yen Jaffe's Reprod Endocrinol Physiol Pathophysiol Clin Manag Eighth Ed. 2019;419:248-255.e3.
2. The Global Cancer Observatory. Cancer Incident in Indonesia. Int Agency Res Cancer. 2020;858:1-2.
3. Rojas K, Stuckey A. Breast Cancer Epidemiology and Risk Factors. Clin Obstet Gynecol. 2016;59(4):651-72.
4. Khan NAJ, Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol. 2021;38(4):1-8.
5. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA - J Am Med Assoc. 2019;321(3):288-300.
6. Nounou MI, Elamrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies supplementary issue: Targeted therapies in breast cancer treatment. Breast Cancer Basic Clin Res. 2015;9:17-34.
7. American Cancer Society. How does radiation work to treat cancer? Am Cancer Soc. 2014;5-6(01):3-9.
8. Kementerian Kesehatan RI. Panduan Nasional Penanganan Kanker Payudara [Internet]. 2015 [cited 2022 Jun 24]; Available from: <http://kanker.kemkes.go.id/guidelines/PNPKPayudara.pdf>
9. Sousa C, Cruz M, Neto A, Pereira K, Peixoto M, Bastos J, et al. Neoadjuvant radiotherapy in the approach of locally advanced breast cancer. ESMO Open. 2020;4(2):1-6.
10. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JAW, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol. 2007;25(15):2127-32.
11. Ramli M. Update Breast Cancer Management. J Fak Kedokt Andalas. 2015;38:28-52.
12. Chen HL, Zhou MQ, Tian W, Meng KX, He HF. Effect of age on breast cancer patient prognoses: A population-based study using the SEER 18 database. PLoS One. 2016;11(10):1-11.
13. Koh J, Kim MJ. Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage. Korean J Radiol. 2019;20(1):69-82.
14. Balabram D, Turra CM, Gobbi H. Survival of patients with operable breast cancer (Stages I-III) at a Brazilian public hospital - a closer look into cause-specific mortality. BMC Cancer. 2013;13.

15. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J Clin Oncol*. 2014;5(3):412–24.
16. Salim EH, Eddy Herman Tanggo, Dwi Hari Susilo. The Relationship between Recurrence Rate and Molecular Subtypes of Breast Cancer in Locally Advance Breast Cancer (LABC) Post Mastectomy: Focus on Comparison of Luminal A and Luminal B. *Biosci Med J Biomed Transl Res*. 2021;5(4):877–81.
17. Bae SY, Kim S, Lee JH, Lee H chul, Lee SK, Kil WH, et al. Poor prognosis of single hormone receptor- positive breast cancer: Similar outcome as triple-negative breast cancer. *BMC Cancer*. 2015;15(1):1–9.
18. Mannell A. The role of ki-67 in breast cancer. *South African J Surg*. 2016;54(2):10–3.
19. Pradhan A, Paudyal P, Sinha A, Agrawal C. Grading, staging and Nottingham prognostic index scoring of breast carcinoma. *J Pathol Nepal*. 2017;7(1):1078–83.
20. Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: A study of 161 708 cases of breast cancer from the SEER program. *Arch Pathol Lab Med*. 2014;138(8):1048–52.
21. Korhonen T, Kuukasjärvi T, Huhtala H, Alarmo EL, Holli K, Kallioniemi A, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. *Breast*. 2013;22(6):1119–24.
22. Ryu YJ, Kang SJ, Cho JS, Yoon JH, Park MH. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. *Med (United States)*. 2018;97(30).
23. Bese NS, Sut PA, Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. *Oncology*. 2005;69(3):214–23.
24. Liu L, Yang Y, Guo Q, Ren B, Peng Q, Zou L, et al. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: A meta-analysis and systematic review. *Radiat Oncol*. 2020;15(1):1–15.
25. Rumah Sakit Universitas Andalas. RS Unand Launching Layanan Radioterapi [Internet]. 2018 [cited 2022 Jun 24]. Available from: <http://rsp.unand.ac.id/artikel/rs-unand-launching-layanan-radioterapi>
26. NIH. What Is Cancer ? Differences between Cancer Cells and Normal Cells. *Natl Cancer Inst*. 2021;1–8.

27. WHO. Breast cancer [Internet]. World Health Organization. 2021 [cited 2022 Jun 24]. Available from: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
28. Kementerian Kesehatan RI. Situasi Penyakit Kanker Indonesia. Pus Data dan Inf Kemenkes RI. 2015;(2):31–3.
29. Sukmayenti S, Sari N. Analisis Determinan Kanker Payudara Pada Wanita di Rsup Dr. M.Djamil Padang Tahun 2018. *J Kesehat*. 2019;7621(1):77–86.
30. Sinuraya ES. Registrasi Kanker Berbasis Stadium di Rumah Sakit Kanker Dharmas 2003-2007. Jakarta; 2012.
31. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. *J Natl Cancer Inst*. 2014;106(5).
32. Dong JY, Qin LQ. Education level and breast cancer incidence: A meta-analysis of cohort studies. *Menopause*. 2020;27(1):113–8.
33. Hussain SK, Altieri A, Sundquist J, Hemminki K. Influence of education level on breast cancer risk and survival in Sweden between 1990 and 2004. *Int J Cancer*. 2008;122(1):165–9.
34. Trewin CB, Strand BH, Weedon-Fekjær H, Ursin G. Changing patterns of breast cancer incidence and mortality by education level over four decades in Norway, 1971-2009. *Eur J Public Health*. 2017;27(1):160–6.
35. van Maaren MC, Rachet B, Sonke GS, Mauguen A, Rondeau V, Siesling S, et al. Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands. *Cancer Epidemiol*. 2022;77(January):0–2.
36. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer Targets Ther*. 2019;11:151–64.
37. Shah R, Rosso K, David Nathanson S. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J Clin Oncol*. 2014;5(3):283–98.
38. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis*. 2018;5(2):77–106.
39. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. *Nat Rev Cancer*. 2012;12(1):68–78.
40. Mehrgou A. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. *Med J Islam Repub Iran*. 2016;
41. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. *Cancer Sci*. 2004;95(11):866–71.

42. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. *Adv Anat Pathol.* 2020;27(1):27–35.
43. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. *Cancer Biol Ther.* 2010;10(10):955–60.
44. Lydiatt WM, Patel SG, Ridge JA, O’Sullivan B, Shah JP. Staging Head and Neck Cancers. *AJCC Cancer Staging Manual.* 2017. 55–65 p.
45. Panigroro S, Hernowo BS, Purwanto H. Panduan Penatalaksanaan Kanker Payudara (Breast Cancer Treatment Guideline). *J Kesehat Masy.* 2019;4(4):1–50.
46. Henderson JA, Duffee D, Ferguson T. *Breast Examination Techniques.* In Treasure Island (FL); 2022.
47. ACS. Breast Cancer Early Detection and Diagnosis American Cancer Society Recommendations for the Early Detection of Breast Cancer. *Am Cancer Soc.* 2016;1–55.
48. Kuzmiak CM, Ko EY, Tuttle LA, Steed D, Zeng D, Yoon SC. Whole Breast Ultrasound: Comparison of the Visibility of Suspicious Lesions with Automated Breast Volumetric Scanning Versus Hand-Held Breast Ultrasound. *Acad Radiol.* 2015;22(7):870–9.
49. Ramadhania DA. Pemeriksaan Radiologi untuk Deteksi Kanker Payudara. *Cermin Dunia Kedokt.* 2017;44(3):226–9.
50. Mann RM, Cho N, Moy L. Breast MRI: State of the art. *Radiology.* 2019;292(3):520–36.
51. McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. *J Nucl Med.* 2016;57:9S-16S.
52. Zaha DC. Significance of immunohistochemistry in breast cancer. *World J Clin Oncol.* 2014;5(3):382–92.
53. Goethals A, Rose J. Mastectomy. In Treasure Island (FL); 2022.
54. Harris JR. *Diseases of the breast.* 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.
55. American Cancer Society. *Breast Cancer: Treating Breast Cancer.* Am Cancer Soc. 2019;1–120.
56. Plesca M, Bordea C, El Houcheimi B, Ichim E, Blidaru A. Evolution of radical mastectomy for breast cancer. *J Med Life.* 2016;9(2):183–6.
57. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: Current advances and future directions. *Int J Med Sci.* 2012;9(3):193–9.
58. Elia AB., Gondhowiardjo SA. Hipofraksinasi Pada Kanker Payudara Stadium Dini. *Radioterapi & Onkologi Indonesia. J Indones Radiat Oncol Soc.* 2013;4(2):39–77.

59. Hashemi FA, Barzegartahamtan M, Mohammadpour RA, Sebzari A, Kalaghchi B, Haddad P. Comparison of conventional and hypofractionated radiotherapy in breast cancer patients in terms of 5-year survival, locoregional recurrence, late skin complications and cosmetic results. *Asian Pacific J Cancer Prev*. 2016;17(11):4819–23.
60. Rastogi K, Jain S, Bhatnagar A, Bhaskar S, Gupta S, Sharma N. A comparative study of hypofractionated and conventional radiotherapy in postmastectomy breast cancer patients. *Asia-Pacific J Oncol Nurs*. 2018;5(1):107–13.
61. Azam AA, Oraby AH, Awad IA, Attalla EM. Study the Influence of Treatment Interruptions in the Radical Irradiation of Breast Cancer. *J Adv Phys*. 2017;13(4):4857–67.
62. Alam A. Chemotherapy Treatment and Strategy Schemes: A Review. *Open Access J Toxicol*. 2018;2(5).
63. Amjad MT, Chidharla A, Kasi A. *Cancer Chemotherapy*. In Treasure Island (FL); 2022.
64. Katzung BG, York N, San C, Athens F, Madrid L, City M. *Basic & Clinical Pharmacology Fourteenth Edition a LANGE medical book*. Basic & Clinical Pharmacology. 2012. 426–427 p.
65. Awan A, Esfahani K. Endocrine therapy for breast cancer in the primary care setting. *Curr Oncol*. 2018;25(4):285–91.
66. Puhalla S, Bhattacharya S, Davidson NE. Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. *Mol Oncol*. 2012;6(2):222–36.
67. Mathew A, Davidson NE. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. *Breast*. 2015;24:S120–5.
68. Kumar P, Sharma A. Gonadotropin-releasing hormone analogs: Understanding advantages and limitations. *J Hum Reprod Sci*. 2014;7(3):170–4.
69. Alwafi Ridho Subarkah. *Pedoman Nasional Pelayanan Kedokteran Kanker Payudara Kementerian Kesehatan RI*. 2018;151(2):10–7.
70. Syaifudin A. Korelasi Antara Ekspresi Cd44 Terhadap Grading Histopatologi, Metastasis, Disease Free Survival, Dan Overall Survival Pada Wanita Penderita Kanker Payudara. *Compos Part A Appl Sci Manuf*. 2020;1(1):1–60.
71. Ayuza M, Harahap WA, Rustam R, Nindrea RD. Faktor yang Berpengaruh Terhadap Disease Free Survival dan Overall Survival pada Pasien Kanker Payudara Usia Muda di Kota Padang Tahun 2008 - 2018. *J Kesehat Andalas*. 2020;9(1S):65–73.

72. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: Population based study. *Br Med J*. 2000;320(7233):474–8.
73. Karihtala P, Jääskeläinen A, Roininen N, Jukkola A. Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital. *BMJ Open*. 2020;10(10):1–6.
74. Wu SG, He ZY, Li Q, Sun JY, Li FY, Lin Q, et al. Prognostic Value of Metastatic Axillary Lymph Node Ratio for Chinese Breast Cancer Patients. *PLoS One*. 2013;8(4):10–4.
75. Narod SA. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. *Curr Oncol*. 2012;19(5):249–53.
76. Breast cancer [Internet]. 2021 [cited 2022 Aug 24]. Available from: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
77. van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. *Int J Cancer*. 2019;144(2):263–72.
78. American Cancer Society. *Understanding a Breast Cancer Diagnosis*, Atlanta. 2016;1–36.
79. Agustina R. Peran Derajat Differensiasi Histopatologik dan Stadium Klinis Pada Rekurensi Kanker Payudara. *Majority*. 2015;4(7):129–34.
80. Yang C, Lei C, Zhang Y, Zhang J, Ji F, Pan W, et al. Comparison of Overall Survival Between Invasive Lobular Breast Carcinoma and Invasive Ductal Breast Carcinoma: A Propensity Score Matching Study Based on SEER Database. *Front Oncol*. 2020;10(December):1–10.
81. Simon A, Manuaba TW. Pengaruh Grading dan Lymphovascular Invasion Terhadap Metastasis Kelenjar Getah Bening Axilla pada Kanker Payudara, Universitas Udayana Bagian / SMF Bedah Onkologi, Fakultas Kedokteran Universitas Ud. 2016;5(6):1–7.
82. He KW, Sun JJ, Liu ZB, Zhuo PY, Ma QH, Liu ZY, et al. Prognostic significance of lymphatic vessel invasion diagnosed by D2-40 in Chinese invasive breast cancers. *Med (United States)*. 2017;96(44).
83. Sánchez C, Domínguez F, Galindo H, Camus M, Oddo D, Villarroel A, et al. Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases. *Rev Med Chil*. 2020;148(9):1233–8.
84. Furrer D, Paquet C, Jacob S, Diorio C. The Human Epidermal Growth Factor Receptor 2 (HER2) as a Prognostic and Predictive Biomarker: Molecular Insights into HER2 Activation and Diagnostic Implications. *Cancer Progn*. 2018;

85. Barcelo A, Duffett-Leger L, Pastor-Valero M, Pereira J, Colugnati FAB, Trapido E. The role of education on Cancer amenable mortality among non-Hispanic blacks & non-Hispanic whites in the United States (1989–2018). *BMC Cancer*. 2021;21(1):1–13.
86. Dyanti GAR, Suariyani NLP. Faktor-Faktor Keterlambatan Penderita Kanker Payudara dalam Melakukan Pemeriksaan Awal ke Pelayanan Kesehatan. 2016;11(2).
87. Sander MA. Profil Penderita Kanker Payudara Stadium Lanjut Baik Lokal Maupun Metastasis Jauh Di Rsup Hasan Sadikin Bandung. *Farmasains J Farm dan Ilmu Kesehat*. 2012;1(2).
88. Diahpradnya Oka Partini P, Nirvana IW, Anda Tusta Adiputra P. Karakteristik kanker payudara usia muda di Subbagian Bedah Onkologi Rumah Sakit Umum Pusat Sanglah tahun 2014-2016. *Intisari Sains Medis*. 2018;9(1):76–9.
89. Sinn HP, Kreipe H. A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. *Breast Care*. 2013;8(2):149–54.
90. Shen S Di, Zhong SZ, Wang CZ, Huang WH. Correlation of lymphovascular invasion with clinicopathological factors in invasive breast cancer: A meta-analysis. *Int J Clin Exp Med*. 2015;8(10):17789–95.
91. Hendrick RE, Monticciolo DL, Biggs KW, Malak SF. Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women. *Cancer*. 2021;127(23):4384–92.
92. Balekouzou A, Yin P, Pamatika CM, Bishwajit G, Nambei SW, Djeintote M, et al. Epidemiology of breast cancer: retrospective study in the Central African Republic. *BMC Public Health*. 2016;16(1):1–10.
93. LaBarge MA, Mora-Blanco EL, Samson S, Miyano M. Breast Cancer beyond the Age of Mutation. *Gerontology*. 2016;62(4):434–42.
94. Suryadinata RV, Wirjatmadi B, Adriani M, Lorensia A. Effect of age and weight on physical activity. *J Public health Res*. 2020;9(2):187–90.
95. Cassidy S, Chau JY, Catt M, Bauman A, Trenell MI. Low physical activity, high television viewing and poor sleep duration cluster in overweight and obese adults; a cross-sectional study of 398,984 participants from the UK Biobank. *Int J Behav Nutr Phys Act*. 2017;14(1):1–10.
96. Kantelhardt EJ, Zerche P, Mathewos A, Trocchi P, Addissie A, Aynalem A, et al. Breast cancer survival in Ethiopia: A cohort study of 1,070 women. *Int J Cancer*. 2014;135(3):702–9.
97. Mursyidah NI, Ashariati A, Kusumastuti EH. Comparison of Breast Cancer 3-years Survival Rate Based on the Pathological Stages. *JUXTA J Ilm Mhs Kedokt Univ Airlangga*. 2019;10(1):38.

98. Caplan L. Delay in breast cancer: Implications for stage at diagnosis and survival. *Front Public Heal.* 2014;2(JUL):1–5.
99. Zhang M, Peng P, Gu K, Cai H, Qin G, Shu XO, et al. Time-varying effects of prognostic factors associated with long-term survival in breast cancer. *Endocr Relat Cancer.* 2018;25(5):509–21.
100. Gómez-Acebo I, Dierssen-Sotos T, Palazuelos-Calderón C, Pérez-Gómez B, Amiano P, Guevara M, et al. Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. *Breast Cancer Res Treat.* 2020;181(3):667–78.
101. Elkablawy MA, Albasri AM, Mohammed RA, Hussainy AS, Nouh MM, Alhujaily AS. Ki67 expression in breast cancer: Correlation with prognostic markers and clinicopathological parameters in Saudi patients. *Saudi Med J.* 2016;37(2):137–41.
102. Nascimento RG do, Otoni KM. Histological and molecular classification of breast cancer: what do we know? *Mastology.* 2020;30:1–8.
103. Barroso-Sousa R, Metzger-Filho O. Differences between invasive lobular and invasive ductal carcinoma of the breast: Results and therapeutic implications. *Ther Adv Med Oncol.* 2016;8(4):261–6.
104. McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. *Breast Cancer Res.* 2021;23(1):1–16.
105. Liu YL, Saraf A, Lee SM, Zhong X, Hibshoosh H, Kalinsky KM, et al. Lymphovascular Invasion is an Independent Predictor of Survival in Breast Cancer after Neoadjuvant Chemotherapy *Ying.* 2016;157(3):555–64.
106. Houvenaeghel G, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, et al. Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. *ESMO Open.* 2021;6(6): 1–10.
107. Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, et al. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. *Breast Cancer Res.* 2017;19(1):1–11.
108. Algazzar MAA, Elsayed EEM, Alhanafy AM, Mousa WA. Breast cancer imaging features as a predictor of the hormonal receptor status, HER2neu expression and molecular subtype. *Egypt J Radiol Nucl Med.* 2020;51(1).
109. Alzaman AS, Mughal SA, Alzaman YS, Alzaman ES. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. *Saudi Med J.* 2016;37(1):37–42.

110. Gnanamuttupulle M, Henke O, Ntundu SH, Serventi F, Mwakipunda LE, Amsi P, et al. Clinicopathological characteristics of breast cancer patients from Northern Tanzania: Common aspects of late stage presentation and triple negative breast cancer. *Ecancermedicalsecience*. 2021;15:1–16.
111. Khambri D, Harahap WA, Yanwirasti Y, ... Pentingnya Pemeriksaan Androgen Reseptor (AR) Terhadap Penderita Karsinoma Payudara di Sumatera Barat. 2016;6(2):39–45.
112. Li LT, Jiang G, Chen Q, Zheng JN. Predict Ki67 is a promising molecular target in the diagnosis of cancer (Review). *Mol Med Rep*. 2015;11(3):1566–72.
113. Widiana IK, Irawan H. Clinical and Subtypes of Breast Cancer in Indonesia. *Asian Pacific J Cancer Care*. 2020;5(4):281–5.
114. Razmjoo S, Haghi N, Tahmasebi Birgani MJ, Arvandi S, Hosseini SM, Shahbazian H, et al. Radiotherapy Interruption in Cancer Patients: Rates and Causes at Ahvaz Golestan Hospital. *Asian Pacific J Cancer Care*. 2020;5(1):33–6.
115. Ying X, Bi J, Ding Y, Wei X, Wei W, Xin F, et al. Management and Outcomes of Patients With Radiotherapy Interruption During the COVID-19 Pandemic. *Front Oncol*. 2021;11(November):1–9.
116. Fisher S, Gao H, Yasui Y, Dabbs K, Winget M. Survival in stage I-III breast cancer patients by surgical treatment in a publicly funded health care system. *Ann Oncol*. 2015;26(6):1161–9.
117. Tan KF, Adam F, Hussin H, Mohd Mujar NM. A comparison of breast cancer survival across different age groups: A multicentric database study in Penang, Malaysia. *Epidemiol Health*. 2021;43:1–13.
118. Sjekloča N, Tomić S, Mrklić I, Vukmirović F, Vučković L, Lovasić IB, et al. Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer. *Med (United States)*. 2020;99(7):1–7.
119. de Boer AZ, van der Hulst HC, de Glas NA, Marang-van de Mheen PJ, Siesling S, de Munck L, et al. Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study. *Oncologist*. 2020;25(1):24–30.
120. Wijayanto A, Pieter JSLA, Prihantono P, Syamsu SA, Thaufix NS, Abdi A. Survivability Rates Based on Molecular Subtype, Stage and Metastasis of 36 months cohort in Breast Cancer Patients. *Nusant Med Sci J*. 2022;7(1):29–38.
121. Liu Y, He M, Zuo WJ, Hao S, Wang ZH, Shao ZM. Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement. *Front Oncol*. 2021;11(April):1–7.

122. Chitapanarux I, Sripan P, Somwangprasert A, Charoentum C, Onchan W, Watcharachan K, et al. Stage-specific survival rate of breast cancer patients in Northern Thailand in accordance with two different staging systems. *Asian Pacific J Cancer Prev.* 2019;20(9):2699–706.
123. Al Farisyi M, Khambri D. Analisis Survival Pasien Kanker Payudara Usia Muda di RSUP DR. M. Djamil Padang Tahun 2008-2017. *J Kesehatan Andalas.* 2018;7(Supplement 4):25.
124. Wetstein SC, de Jong VMT, Stathonikos N, Opdam M, Dackus GMHE, Pluim JPW, et al. Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images. *Sci Rep.* 2022;12(1):1–12.
125. Rossi L, Laas E, Mallon P, Guinebretiere J, Lerebours F, Rouzier R, et al. Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. *Br J Cancer.* 2015;(June):996–1002.
126. Sejati F, Rizki K, Yohana R. Hubungan Derajat Histopatologi Dan Invasi Limfovaskular Terhadap Metastasis Kelenjar Getah Bening Aksila Pada Kanker Payudara Dini. *Med Kartika J Kedokt dan Kesehat.* 2019;3(Volume 3 No 1):37–49.
127. Oshi M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Endo I, et al. Degree of early estrogen response predict survival after endocrine therapy in primary and metastatic ER-positive breast cancer. *Cancers (Basel).* 2020;12(12):1–16.
128. Saha Roy S, Vadlamudi RK. Role of Estrogen Receptor Signaling in Breast Cancer Metastasis. *Int J Breast Cancer.* 2012;2012:1–8.
129. Yao N, Song Z, Wang X, Yang S, Song H. Prognostic impact of progesterone receptor status in Chinese estrogen receptor positive invasive breast cancer patients. *J Breast Cancer.* 2017;20(2):160–9.
130. Li Z, Wei H, Li S, Wu P, Mao X. The Role of Progesterone Receptors in Breast Cancer. 2022;16:305–314.
131. Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, et al. Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy. *Ann Oncol.* 2008;19(3):465–72.
132. Rahma H, Nisa K, Studi P, Dokter P, Kedokteran F, Lampung U, et al. Peran Human Epidermal Growth Factor Receptor-2 pada Kanker Payudara Role of Human Epidermal Growth Factor Receptor-2 in Breast Cancer. *J Agromedicine Unila.* 2018;5(2):644–7.
133. Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. *Oncotarget.* 2016;7(21):1–9.

134. Fu F, Guo W, Lin Y, Zeng B, Qiu W, Huang M, et al. Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. *J Transl Med.* 2018;16(1):1–12.
135. Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. *Front Mol Biosci.* 2014;1(NOV):1–9.
136. Prajogi G Ben, Djakaria M. Interupsi dalam Proses Terapi Radiasi. *J Indones Radiat Oncol Soc.* 2010;1(1):6–19.
137. Ma SJ, Oladeru OT, Singh AK. Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. *JAMA Netw open.* 2020;3(8):e2013973.
138. Noe JF, Bush MA. Endocrine Therapy for Breast Cancer. *J Nurse Pract.* 2021;17(2):177–81.

